|
related topics |
{product, candidate, development} |
{property, intellectual, protect} |
{provision, law, control} |
{stock, price, operating} |
{stock, price, share} |
{cost, operation, labor} |
{acquisition, growth, future} |
{condition, economic, financial} |
{product, market, service} |
{product, liability, claim} |
{control, financial, internal} |
{cost, regulation, environmental} |
{personnel, key, retain} |
{cost, contract, operation} |
|
Risks Related To Our Business
We are dependent on our product discovery and development collaborators for all of our revenue and we are dependent on our current and any future product discovery and development collaborators to develop and commercialize any flavor ingredients we may discover.
Our business and operating results may be adversely affected by unfavorable economic and market conditions.
We may not be able to negotiate additional collaboration agreements having terms satisfactory to us or at all.
We may not be successful in developing flavor ingredients useful for formulation into products.
If we or our collaborators are unable to obtain and maintain the
GRAS determination or other regulatory approval required before certain of our flavor ingredients can be incorporated into products that are sold, we would be unable to commercialize our flavor ingredients and our business would be adversely affected.
Even if we or our collaborators receive regulatory approval and incorporate our flavor ingredients into products, those products may never be commercially successful.
We have a history of operating losses and we may not achieve or maintain profitability.
We expect that our results of operations will fluctuate from period to period, and this fluctuation could cause our stock price to decline.
We may seek additional capital to fund our operations.
If we elect to modify our business operations in order to reduce our expenses, our research, discovery and development programs could be negatively impacted.
If we lose our key personnel or are unable to attract and retain qualified personnel, it could adversely affect our business.
We may encounter difficulties managing our growth, which could adversely affect our business.
We rely on third parties to manufacture our flavor ingredients on a commercial scale.
If we acquire products, technologies or other businesses, we will incur a variety of costs, may have integration difficulties and may experience numerous other risks that could adversely affect our business.
Risks Related To Our Industry
Our ability to compete in the flavor ingredient market may decline if we do not adequately protect our proprietary technologies.
Many of the patent applications we and our licensors have filed have not yet been substantively examined and may not result in patents being issued.
Disputes concerning the infringement or misappropriation of our proprietary rights or the proprietary rights of others could be time consuming and extremely costly and could delay our research and development efforts.
If we are unable to protect our trade secrets and other proprietary information, we could lose any competitive advantage we may have, which could adversely affect our business.
Many potential competitors, including those who have greater resources and experience than we do, may develop products or technologies that make ours obsolete or noncompetitive.
We may be sued for product liability and exposed to other product safety-related risks, which could adversely affect our business and harm our reputation.
We use hazardous materials. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.
Risks Related To Our Common Stock
The price of our common stock is volatile.
Anti-takeover provisions in our charter documents and under Delaware law may make an acquisition of us more complicated and the removal and replacement of our directors and management more difficult.
Our shareholder rights plan may hinder or prevent change of control transactions.
We have never paid cash dividends on our capital stock and we do not anticipate paying dividends in the foreseeable future.
Full 10-K form ▸
|
|
related documents |
1123979--2/12/2009--SENOMYX_INC |
1066833--3/15/2006--DOV_PHARMACEUTICAL_INC |
1033025--3/17/2006--PRAECIS_PHARMACEUTICALS_INC |
805326--3/25/2010--EMISPHERE_TECHNOLOGIES_INC |
805326--3/16/2009--EMISPHERE_TECHNOLOGIES_INC |
1162192--3/31/2009--AVALON_PHARMACEUTICALS_INC |
805326--3/6/2007--EMISPHERE_TECHNOLOGIES_INC |
1029142--3/16/2007--DYNAVAX_TECHNOLOGIES_CORP |
819050--2/23/2007--VICAL_INC |
1029142--3/16/2006--DYNAVAX_TECHNOLOGIES_CORP |
819050--3/10/2006--VICAL_INC |
895051--3/13/2009--ENTREMED_INC |
1005201--3/16/2006--DEPOMED_INC |
887151--3/13/2006--ORTHOLOGIC_CORP |
1140028--3/16/2006--Hana_Biosciences_Inc |
730272--6/9/2006--REPLIGEN_CORP |
1123979--2/23/2007--SENOMYX_INC |
1123979--2/14/2008--SENOMYX_INC |
877902--3/8/2006--NEOSE_TECHNOLOGIES_INC |
882796--3/9/2010--BIOCRYST_PHARMACEUTICALS_INC |
819050--3/3/2009--VICAL_INC |
819050--2/25/2010--VICAL_INC |
818033--3/31/2006--AP_PHARMA_INC_/DE/ |
819050--3/3/2008--VICAL_INC |
1099215--7/31/2007--PROTALEX_INC |
64978--3/30/2010--MERCK_SHARP_&_DOHME_CORP. |
907562--3/4/2009--DYAX_CORP |
824068--3/14/2008--ATS_MEDICAL_INC |
887359--9/13/2006--AASTROM_BIOSCIENCES_INC |
919745--3/16/2007--POINT_THERAPEUTICS_INC |
|